Metformin and longevity
Pro Research Analysisby 
Searched over 200M research papers
Metformin and Lifespan Extension: Evidence from Animal and Cellular Models
Research in animal models, such as mice and the nematode C. elegans, consistently shows that metformin can extend lifespan and healthspan. In mice, long-term metformin treatment starting at middle age led to longer life and improved health, mimicking some benefits of calorie restriction, such as better physical performance, increased insulin sensitivity, and reduced cholesterol levels. These effects are linked to increased AMP-activated protein kinase (AMPK) activity, enhanced antioxidant protection, and reduced inflammation and oxidative damage 49. In C. elegans, metformin extends lifespan through mechanisms involving the lysosomal pathway, specifically by coordinating mTORC1 and AMPK signaling, and through mitohormesis, where increased reactive oxygen species (ROS) production triggers a pro-longevity response via the antioxidant peroxiredoxin PRDX-2 15.
At the cellular level, metformin has been shown to delay aging in human cells by upregulating antioxidant enzymes like glutathione peroxidase 7 (GPx7) through the Nrf2 pathway, which helps protect cells from oxidative stress and premature senescence . In prediabetic humans, metformin improved markers associated with longevity, such as increased SIRT1 expression and favorable changes in plasma N-glycans, which are considered surrogate markers of aging .
Metformin’s Mechanisms: AMPK, mTOR, and Antioxidant Pathways
Metformin’s potential anti-aging effects are thought to be mediated by several key molecular pathways. The drug activates AMPK, a central regulator of cellular energy, which in turn inhibits mTOR, a pathway associated with aging and cell growth. This inhibition promotes autophagy and reduces chronic inflammation, both of which are linked to healthier aging 69. Metformin also enhances antioxidant defenses, reducing oxidative stress, which is a major contributor to cellular aging 148.
Human Studies: Healthspan vs. Lifespan
While animal and cellular studies are promising, evidence in humans is more nuanced. Observational studies and clinical trials suggest that metformin may improve healthspan—the period of life spent in good health—by reducing the risk of diseases like diabetes, cardiovascular disease, cognitive decline, and cancer 26910. However, whether metformin actually increases overall lifespan in humans remains controversial. Some studies show short-term benefits in longevity for people with type 2 diabetes taking metformin, but these benefits may not persist over longer periods, and the negative effects of diabetes itself may outweigh the drug’s positive impact on lifespan .
Ongoing Research and Future Directions
Large clinical trials, such as the TAME (Targeting Aging with Metformin) study, are underway to determine whether metformin can be recommended as an anti-aging therapy for people without diabetes 210. Current evidence suggests that metformin’s main benefits in humans are likely indirect, stemming from its ability to improve metabolic health, reduce oxidative stress, and protect vascular function 269.
Conclusion
Metformin shows clear potential to promote longevity and delay aging in animal and cellular models, primarily through pathways involving AMPK activation, mTOR inhibition, and enhanced antioxidant defenses 1458+1 MORE. In humans, metformin appears to improve healthspan by reducing the risk of age-related diseases, but its ability to extend overall lifespan is still debated and requires further long-term study 2310. Ongoing clinical trials will help clarify whether metformin can be widely recommended as an anti-aging intervention.
Sources and full results
Most relevant research papers on this topic